Guanxinning Tablet Alleviates Post-Ischemic Stroke Injury Via Regulating Complement and Coagulation Cascades Pathway and Inflammatory Network Mobilization
Yule Wang,Yiran Li,Yue Zhou,Yue Gao,Lu Zhao
DOI: https://doi.org/10.2147/dddt.s479881
IF: 4.3188
2024-09-19
Drug Design Development and Therapy
Abstract:Yule Wang, 1 Yiran Li, 2 Yue Zhou, 2 Yue Gao, 1 Lu Zhao 2 1 Zhejiang Key Laboratory of Traditional Chinese Medicine for the Prevention and Treatment of Senile Chronic Diseases, Department of Geriatrics, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, People's Republic of China; 2 Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, People's Republic of China Correspondence: Lu Zhao; Yue Gao, Email ; Background: Currently, ischemic stroke (IS) continues to significantly contribute to functional deterioration and reduced life quality. Regrettably, the choice of neuro-rehabilitation interventions to enhance post-IS outcomes is limited. Guanxinning tablet (GXNT), a multi-component medicine composed of Danshen and Chuanxiong, has demonstrated neuroprotective potential against ischemic brain injury and diabetic encephalopathy. However, the therapeutic impact of GXNT on post-IS functional outcomes and pathological injury, as well as the underlying molecular mechanisms and anti-IS active substances, remain unclear. Methods: To answer the above questions, neurological and behavioral assessment, cerebral lesions, and blood-brain barrier (BBB) integrity were combined to comprehensively investigate GXNT's pharmacodynamic effects against post-IS injury. The possible molecular mechanisms were revealed through transcriptome sequencing coupled with experimental verification. Furthermore, the brain tissue distribution of main components in GXNT, behavioral changes of IS zebrafish, and molecular docking were integrated to identify the anti-IS active compounds. Results: Treatment with GXNT significantly mitigated the functional deficits, cerebral cortex lesions, and BBB disruption following IS. Transcriptome sequencing and bioinformatics analysis suggested that complement and coagulation cascades as well as inflammation might play crucial roles in the GXNT's therapeutic effects. Molecular biology experiments indicated that GXNT administration effectively normalized the abnormal expression of mRNA and protein levels of key targets related to complement and coagulation cascades (eg C3 and F7) and inflammation (eg MMP3 and MMP9) in the impaired cortical samples of IS mice. The locomotor promotion in IS zebrafish as well as favorable affinity with key proteins (C3, F7, and MMP9) highlighted anti-IS activities of brain-permeating constituents (senkyunolide I and protocatechuic acid) of GXNT. Conclusion: Taken together, these intriguing findings indicate that GXNT intervention exerts a beneficial effect against post-IS injury via regulating the complement and coagulation cascades pathway and mobilizing inflammatory network. Senkyunolide I and protocatechuic acid show promise as anti-IS active compounds. Keywords: Guanxinning tablet, post-ischemic stroke injury, complement and coagulation cascades, inflammatory network mobilization, active substance Graphical Globally, ischemic stroke (IS) affected approximately 7.59 million individuals, leading to 3.48 million IS-related deaths, as per data from the Global Burden of Disease Study 2020. 1 Despite enormous effort to manage IS risk factors and optimize IS care, IS assumes the major responsibility for severe long-term disability and high mortality worldwide. 1 Ischemic brain injury involves a series of pathological events, encompassing energy-dependent ion pumps and channels failures, excitotoxicity, calcium overload, mitochondrial dysfunction, increased oxidative stress, destruction of blood–brain barrier (BBB), inflammatory responses, and eventually cell death. 2 Although advances in better understanding the pathogenesis of IS, intravenous thrombolysis and mechanical thrombectomy remain the standard therapeutic options. 3 However, the limitation of thrombolytic therapy (eg narrow therapeutic window, thrombolysis-associated hemorrhagic transformation, and reperfusion injury) urgently calls for alternatives. 4 In China, Salvia miltiorrhiza Bunge (Danshen) and Ligusticum wallichii Franch. (Chuanxiong) have been widely employed as representative Chinese medicines to invigorate blood circulation and remove stasis in the context of cardiovascular and cerebrovascular diseases. 5,6 Guanxinning tablet (GXNT), a formulation composed of extracts from Danshen and Chuanxiong in a 1:1 ratio, was approved by the National Medical Products Administration of China in 2015 for treating patients with stable exertional angina pectoris Grade I or II linked to heart-blood stagnation syndrome in traditional Chinese medicine. 7–9 Chemical profiling o -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal